News
Growing Confidence in Biosimilars?
MediaSource
Today, Cardinal Health released its third edition of Rheumatology Insights, a research report based on surveys with more than 100 rheumatologists nationwide that focuses on key trends
Infection: a Leading Cause of Death in Lupus
Analysis of a national database of hospital discharges from Spain shows that infections accounted for 25% of lupus deaths, making infection the most common cause of death in SLE.
Update to Axial Spondyloarthritis Guidance
MedPage Today
EULAR and the Assessment of SpondyloArthritis International Society (ASAS) has updated their guidance on axial spondyloarthritis (axSpA) management.
New ACR/EULAR Guideline Expands RA Remission Definition
MedPage Today
Newly released guidance for defining remission in rheumatoid arthritis (RA) is expected to increase the number of patients achieving it while maintaining its ability to predict good objective outcomes.
Increasing Prevalence of RA, PsA and AS in the UK
Electronic health record (EHR) database analysis from the United Kingdom suggests an increasing number of rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritits (SpA) patients in England.
Increasing Risk of Lupus Nephritis
Population based study from Minnesota shows that the incidence of lupus nephritis (LN) in the US has increased in the last four decades and that LN patients have poorer outcomes with high rates of ESRD and mortality rates six times that of the general population.
2022 ASAS-EULAR Guidelines for Axial Spondyloarthritis
Assessment of SpondyloArthritis international Society (ASAS) and EULAR have published their 2022 update and recommendations for the management of axial spondyloarthritis (axSpA).
FDA Approves Upadacitinib for Non-Radiographic Axial Spondyloarthritis
On Friday October 21st the U.S. Food and Drug Administration approved upadacitinib (Rinvoq) for the treatment of active non-radiographic axial spondyloarthritis in patients with objective signs of inflammation who have had an inadequate response or intolerance to tumor necrosis factor blocker therapy.
ACR Award Winners (10.21.2022)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Highlighted discussion of implantable stimulators, urine proteomics and gut-immune responses to Prevotella in RA.
Vaccination Cut Long COVID Risk for Rheum Patients
MedPage Today
Pregnancy Outcomes with Belimumab
Pregnancy in systemic lupus erythematosus (SLE) is fraught with problems of adverse pregnancy outcomes, more pregnancy loss and birth defects. Now a study of SLE pregnancies exposed to belimumab (BEL) shows and expected rate of pregnancy loss but a variable rate of birth defects.
Prevotella Immune Response in Both Pre-Clinical & Established RA
EurekAlert! and Jack Cush
In a recent analysis published in Arthritis & Rheumatology, people at risk for rheumatoid arthritis (RA) and those with the disease had elevated blood levels of antibodies against a Prevotella copri (Pc).
Miners Face Increased Risk of Rheumatoid Arthritis
MedPage Today
Add "hard rock" mining to the list of occupations associated with high rates of rheumatoid arthritis (RA), a new study indicated, with silica exposure the presumed malefactor.
CRTAC1- a Novel Biomarker for Osteoarthritis
EurekAlert!
Scientists at deCODE genetics a subsidiary of Amgen report in Arthritis & Rheumatology that a novel plasma protein (cartilage acidic protein-1; CRTAC1) is a potential biomarker of osteoarthritis (OA) through its association with OA risk and progression to joint replacement.